UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
January 16, 2020
COMMISSION FILE NUMBER001-39081
BioNTech SE
(Translation of registrant’s name into English)
An der Goldgrube 12
D-55131 Mainz
Germany
+496131-9084-0
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED AS PART OF THIS FORM6-K
On January 16, 2020, BioNTech SE (the “Company”) and Neon Therapeutics, Inc. issued a joint press release announcing their entry into an Agreement and Plan of Merger, dated as of January 15, 2020. A copy of the joint press release is attached hereto as Exhibit 99.1.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BioNTech SE | ||
By: | /s/ Dr. Sierk Poetting | |
| ||
Name: Dr. Sierk Poetting | ||
Title: Chief Financial Officer and Chief Operating Officer |
Date: January 16, 2020
EXHIBIT INDEX
Exhibit | Description of Exhibit | |
99.1 | Joint Press Release datedJanuary 16, 2020—BioNTech to acquire Neon to strengthen global leadership position in T cell therapies |